Skip to main content

New at Switzerland Innovation Park Basel Area: Coretag

| News

New at Switzerland Innovation Park Basel Area: Coretag


Coretag, a new dynamic biotech company, launches a radioligand platform technology for a range of therapeutic and diagnostic purposes. A radioligand is a radioactive biochemical that is used for diagnostic and therapeutic procedures or for studying the body’s receptor systems. Injected into the relevant tissue or administered into the bloodstream, the radioligand binds to its receptor on tumor cells surfaces. Coretag is determined to rapidly improve care with this platform technology.

Coretag: Elmer Monster, Ermond van Beek, Markwin Maring and Jan van Bodegom (from left to right), img: Roderik van Nispen

Coretag aims to launch an application named NC-Scan for use in patients in 2021. Based on selectively binding to necrotic cells, the NC-Scan will be the world’s first clinical application to determine chemotherapy efficacy within the first week of therapy. Clinical trials with patients with specific solid tumors will start early 2020 at world-renowned leading cancer institutes in Europe and the USA.

This application is a basis for the development of therapeutic agents. Two radioligands therapeutics are in the pipeline, both for the treatment of solid tumor cancer-types. Based on brachy-therapy and hyperthermia, they will have major impact as adjuvant to many existing forms of cancer therapies that are not 100% effective yet.

Coretag’s executive team, originally from the Netherlands, sets its base at the Switzerland Innovations Park Basel Area. They work focused on developing their business. “We are very happy with this location. The atmosphere is dynamic and based on progress. That is how we stand. Great to be here”, says CFO Elmer Monster.


Coretag on LinkedIn

Share this article

Sign up to receive our newsletter in your inbox.

You might also be interested in

biGENIUS receives 2 million euros for new cloud product

Software company biGENIUS, based in the Basel Area, has secured financing of 2 million euros. This funding was granted following...
Read More

Opterion Health secures investment of 6.5 million Swiss francs

Opterion Health has raised a total of 6.5 million Swiss francs as part of a financing round. The company, which...
Read More

TOLREMO receives 39 million US dollars in investments

TOLREMO Therapeutics has concluded a series A funding round with 39 million US dollars. The biotech company based in Basel...
Read More

Mazars opens tenth Swiss office in Basel

Mazars is now also present in Basel with a subsidiary as of September 1. This is the tenth Swiss location...
Read More

Medtech in Switzerland – bringing together traditional skills and hightech industry

How the intersection of traditional and novel skillsets in the Jura area is propelling Switzerland into a new era of...
Read More

Fondation Botnar supporting further research into pediatric health

The Basel-based Botnar Research Centre for Child Health has received a further donation of 50 million Swiss francs from the...
Read More

Do you have a question? We'd like to hear from you.